Role and research progress of gut microbiota in uveitis
10.3980/j.issn.1672-5123.2025.1.12
- VernacularTitle:肠道菌群在葡萄膜炎中的作用与研究进展
- Author:
Yingcheng LIN
1
;
Qiuming HU
1
;
Min ZHOU
1
;
Jinqing LIU
1
Author Information
1. Guangxi University of Chinese Medicine, Nanning 530220, Guangxi Zhuang Autonomous Region, China
- Publication Type:Journal Article
- Keywords:
gut microbiota;
uveitis;
gut-eye axis;
birdshot chorioretinopathy;
phage therapy;
fecal microbial transplantation
- From:
International Eye Science
2025;25(1):64-69
- CountryChina
- Language:Chinese
-
Abstract:
Uveitis is a blinding inflammatory disease that affects multiple structures within the eye, posing significant risks to patients' vision and mental health. Current treatments mainly involve glucocorticoids and immunosuppressants, which are associated with significant side effects, high relapse rates, and substantial costs. Recent research suggests that the gut microbiota may play a role in the development of uveitis through the gut-eye axis, with related metabolites also influencing disease progression. Modulating the gut microbiota or its metabolites could offer new therapeutic avenues for uveitis. This review explores the relationship between gut microbiota and various uveitis-associated diseases, such as systemic sarcoidosis, Vogt-Koyanagi-Harada syndrome, Behcet's disease, multiple sclerosis, and birdshot chorioretinopathy. It also discusses advancements in microbiota-related therapies, including probiotics and prebiotics, antibiotics, immunomodulators, phage therapy, and fecal microbiota transplantation. The aim is to provide a reference for the development of new therapies targeting specific microbial communities and genetic markers associated with uveitis, thereby promoting the realization of precision medicine.
